SESSION TITLE: Student/Resident Case Report Poster - Pulmonary Vascular Disease II
SESSION TYPE: Student/Resident Case Report Poster
PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM
INTRODUCTION: Riociguat is approved for the treatment of adults with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). It is marketed with a warning against co-administration with nitric oxide donors in any form due to a risk of hypotension, although the supporting data is limited.